Greg Coffey

1.4k total citations
44 papers, 1.0k citations indexed

About

Greg Coffey is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Greg Coffey has authored 44 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 17 papers in Immunology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Greg Coffey's work include Chronic Lymphocytic Leukemia Research (27 papers), Lymphoma Diagnosis and Treatment (16 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Greg Coffey is often cited by papers focused on Chronic Lymphocytic Leukemia Research (27 papers), Lymphoma Diagnosis and Treatment (16 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Greg Coffey collaborates with scholars based in United States, United Kingdom and Switzerland. Greg Coffey's co-authors include Uma Sinha, Anjali Pandey, Y. Lynn Wang, Yvonne Pak, Stanley J. Hollenbach, Dale C. Baker, Francis DeGuzman, Pamela B. Conley, Pin Lu and Janet L. Neisewander and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Greg Coffey

42 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Greg Coffey United States 17 395 385 356 253 220 44 1.0k
Urte Gayko United States 12 352 0.9× 203 0.5× 198 0.6× 289 1.1× 301 1.4× 27 987
Antonella Vallario Italy 12 369 0.9× 389 1.0× 295 0.8× 157 0.6× 290 1.3× 17 857
Kenneth Nakahara United States 12 798 2.0× 316 0.8× 264 0.7× 361 1.4× 385 1.8× 15 1.6k
Peter Kjellén Sweden 12 163 0.4× 415 1.1× 174 0.5× 93 0.4× 88 0.4× 16 652
Neelam Shirsat India 22 692 1.8× 174 0.5× 233 0.7× 37 0.1× 193 0.9× 53 1.1k
Svetlana Gaidarova United States 18 1.1k 2.8× 630 1.6× 149 0.4× 259 1.0× 722 3.3× 43 1.9k
Raghuveer Singh Mali United States 19 705 1.8× 384 1.0× 248 0.7× 51 0.2× 149 0.7× 44 1.3k
Kathy Strauch United States 9 336 0.9× 919 2.4× 96 0.3× 58 0.2× 173 0.8× 10 1.3k
Ida Casella Italy 15 961 2.4× 186 0.5× 170 0.5× 93 0.4× 323 1.5× 24 1.4k
Günter Eisele Switzerland 16 450 1.1× 462 1.2× 273 0.8× 70 0.3× 433 2.0× 27 1.2k

Countries citing papers authored by Greg Coffey

Since Specialization
Citations

This map shows the geographic impact of Greg Coffey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Coffey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Coffey more than expected).

Fields of papers citing papers by Greg Coffey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Coffey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Coffey. The network helps show where Greg Coffey may publish in the future.

Co-authorship network of co-authors of Greg Coffey

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Coffey. A scholar is included among the top collaborators of Greg Coffey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Coffey. Greg Coffey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horwitz, Steven M., Tatyana Feldman, Jing Christine Ye, et al.. (2025). Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. Leukemia & lymphoma. 66(6). 1100–1110. 5 indexed citations
2.
Fraschilla, Isabella, et al.. (2024). An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin. Journal of Clinical Investigation. 134(4). 5 indexed citations
3.
Coffey, Greg, Jiajia Feng, Anjali Pandey, et al.. (2018). Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. Clinical Cancer Research. 25(4). 1174–1184. 29 indexed citations
4.
Blunt, Matthew D., Stefan Koehrer, Rachel Dobson, et al.. (2016). The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(9). 2313–2324. 54 indexed citations
5.
Coffey, Greg, Francis DeGuzman, Yvonne Pak, et al.. (2014). The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer. Journal of Pharmacology and Experimental Therapeutics. 351(3). 538–548. 73 indexed citations
6.
Patel, Manish R., Paul A. Hamlin, Donald K. Strickland, et al.. (2014). A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies. Blood. 124(21). 3103–3103. 1 indexed citations
7.
Flinn, Ian W., Manish R. Patel, Nina D. Wagner‐Johnston, et al.. (2014). Pharmacokinetics and pharmacodynamics of the dual syk/jak inhibitor PRT062070 (cerdulatinib) in patients with advanced B-cell malignancies.. Journal of Clinical Oncology. 32(15_suppl). 2619–2619. 2 indexed citations
8.
Ma, Jiao, Greg Coffey, Pin Lu, et al.. (2013). Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity In Both ABC and GCB Types Of Diffuse Large B Cell Lymphoma. Blood. 122(21). 1833–1833. 1 indexed citations
9.
Spurgeon, Stephen E., Greg Coffey, Luke B. Fletcher, et al.. (2012). The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia. Journal of Pharmacology and Experimental Therapeutics. 344(2). 378–387. 40 indexed citations
10.
Coffey, Greg, Francis DeGuzman, Lynn Kamen, et al.. (2012). PRT062070: A Dual Syk/JAK Inhibitor with Potent Immune Regulatory Capacity in Rodent Models of Inflammation and Cancer.. Blood. 120(21). 2764–2764. 4 indexed citations
11.
Hoellenriegel, Julia, Greg Coffey, Uma Sinha, et al.. (2012). Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 26(7). 1576–1583. 114 indexed citations
12.
Jones, G. Morgan, et al.. (2011). Impact of Early Initiation of Methadone in Trauma Patients Requiring Mechanical Ventilation. Critical Care Medicine. 39(12). 50.
13.
Coffey, Greg, Francis DeGuzman, Mayuko Inagaki, et al.. (2011). Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics. 340(2). 350–359. 91 indexed citations
14.
Coffey, Greg, Ranjani Rajapaksa, Raymond Liu, et al.. (2009). Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. PubMed Central. 44 indexed citations
15.
Coffey, Greg, et al.. (2005). TISSUE DISTRIBUTION AND RECEPTOR-MEDIATED CLEARANCE OF ANTI-CD11A ANTIBODY IN MICE. Drug Metabolism and Disposition. 33(5). 623–629. 26 indexed citations
16.
Coffey, Greg, Eric Stefanich, Susan L. Palmieri, et al.. (2004). In Vitro Internalization, Intracellular Transport, and Clearance of an Anti-CD11a Antibody (Raptiva) by Human T-Cells. Journal of Pharmacology and Experimental Therapeutics. 310(3). 896–904. 41 indexed citations
17.
Neisewander, Janet L., Rita A. Fuchs, Ly T.L. Tran-Nguyen, et al.. (2004). Increases in Dopamine D3 Receptor Binding in Rats Receiving a Cocaine Challenge at Various Time Points after Cocaine Self-Administration: Implications for Cocaine-Seeking Behavior. Neuropsychopharmacology. 29(8). 1479–1487. 98 indexed citations
18.
Coffey, Greg. (2000). An alternate form of Ku80 is required for DNA end-binding activity in mammalian mitochondria. Nucleic Acids Research. 28(19). 3793–3800. 30 indexed citations
19.
Coffey, Greg, Uma Lakshmipathy, & Colin Campbell. (1999). Mammalian mitochondrial extracts possess DNA end-binding activity. Nucleic Acids Research. 27(16). 3348–3354. 43 indexed citations
20.
Duggan, Catherine, et al.. (1999). Human Chromosomal Localization, Tissue/Tumor Expression, and Regulatory Function of the ets Family Gene EHF. Biochemical and Biophysical Research Communications. 264(1). 119–126. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Urte Gayko Breakdown of academic impact, for papers by Antonella Vallario Breakdown of academic impact, for papers by Kenneth Nakahara Breakdown of academic impact, for papers by Peter Kjellén Breakdown of academic impact, for papers by Neelam Shirsat Breakdown of academic impact, for papers by Svetlana Gaidarova Breakdown of academic impact, for papers by Raghuveer Singh Mali Breakdown of academic impact, for papers by Kathy Strauch Breakdown of academic impact, for papers by Ida Casella Breakdown of academic impact, for papers by Günter Eisele
Rankless by CCL
2026